On December 11, Gelonghui reported that Hebei Changshan Biochemical Pharmaceutical (300255.SZ) announced that its fifth Board of Directors' eighteenth meeting and the fifth Supervisory Board's fourteenth meeting on December 11, 2024, reviewed and approved the proposal regarding the conclusion of the fundraising investment project and the permanent supplement of surplus raised funds to working capital, agreeing to conclude the fundraising investment project "Annual production of 35 tons of heparin series Active Pharmaceutical Ingredient products project" and permanently supplement the surplus raised funds to working capital.
常山药业(300255.SZ)：拟将“年产35吨肝素系列原料药产品项目”结项 并将节余募资永久补充流动资金
Hebei Changshan Biochemical Pharmaceutical (300255.SZ): Plans to conclude the "Annual production of 35 tons of heparin series Active Pharmaceutical Ingredient product project" and permanently supplement working capital with the surplus fundraising.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated